Outside China, MSD has rights to sac-TMT under the terms of a partnership signed in 2022, which involved a $17 million upfront payment and could be worth up to $1.4 billion. While the identity of ...
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback